Newsroom
Sorted by: Latest
-
LIB Therapeutics Launches LEROCHOL® (lerodalcibep-liga) in the United States with a Patient-First Approach to Access and Affordability
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company, today announced the U.S. commercial launch of LEROCHOL® (lerodalcibep-liga) Injection 300 mg/1.2 mL, a once-monthly, self-administered third-generation Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor. LEROCHOL is FDA approved as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous famili...
-
Tyler Technologies, Inc. Announces Proposed Offering of Convertible Senior Notes Due 2031
PLANO, Texas--(BUSINESS WIRE)--Tyler Technologies announces proposed offering of convertible senior notes due 2031....
-
CMI Financial Group Secures Senior Financing from Royal London Asset Management
TORONTO--(BUSINESS WIRE)--CMI Financial Group (“CMI”), a leading Canadian alternative mortgage lender and financial services platform, today announced the closing of a senior financing facility with Royal London Asset Management (“RLAM”), expanding CMI’s ability to help more Canadians achieve homeownership through alternative lending. With approximately £199 billion in assets under management, RLAM is one of the United Kingdom’s largest and most respected asset managers. The facility will accel...
-
Dream Finders Homes Proposes to Acquire Beazer Homes for $25.75 Per Share in Cash
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Dream Finders Homes, Inc. (the “Company”, “Dream Finders”) (NYSE: DFH), announced today that it has submitted a proposal to the board of directors (the “Board”) of Beazer Homes USA, Inc. (“Beazer”) to acquire all outstanding shares of Beazer in an all-cash transaction at a price of $25.75 per share, a cash premium of approximately 40% over Beazer’s closing share price on May 5, 2026. The proposed transaction reflects a total equity value of approximately $70...
-
Lysoway Therapeutics Announces Phase I Dosing of LW-1017, the First TRPML1 Agonist to Enter Clinical Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lysoway Therapeutics today announced that the first participant has been successfully dosed on May 5, 2026 in the Company’s Phase I clinical trial of LW-1017, a potent, selective, and highly brain-penetrant small-molecule TRPML1 agonist being developed for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. The Phase I study is being conducted in Melbourne, Australia and is designed to evaluate the safety, tolerability, and pharma...
-
Alex Nikulin, CFP® Joins Holistic Planning, Establishing Firm’s First New England Office
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Holistic Planning, a national fee-only registered investment advisory firm with more than $1.25 billion in assets under management, today announced that Alex Nikulin, CFP® has joined the firm and established its first office in New England. Based in Portsmouth, New Hampshire, Nikulin serves individuals, families, and business owners across the region with comprehensive financial planning, investment management, and integrated income tax services. The Portsmout...
-
BrilliA Inc. Partners with HH4K Group to Expand Indonesia Manufacturing
SINGAPORE--(BUSINESS WIRE)--BrilliA Inc. (NYSE American: BRIA) (“BrilliA” or the “Company”) today announced, through its subsidiaries Bra Pro Limited and PT Mirae Asia Pasifik, a strategic alliance with Hung Hon (4K) Limited (“HH4K Group” or “HH4K”) to expand localized component manufacturing in Indonesia. This alliance marks a significant step forward in BrilliA’s commitment to building a resilient, diversified, and asset-light supply chain across Southeast Asia. As the first milestone of the...
-
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) following progression after standard first-line therapy. epNECs are an aggressive mal...
-
Leading Independent Proxy Advisory Firm Glass Lewis Joins Egan-Jones in Recommending Shareholders Vote AGAINST Chairman Mark Patterson at Americold’s Annual Meeting
DALLAS--(BUSINESS WIRE)--Sieve Capital LLC (collectively with its affiliates, “Sieve” or “we”), a shareholder of Americold Realty Trust, Inc. (“Americold” or the “Company”) (NYSE: COLD), today announced that a second independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has joined Egan-Jones Proxy Services (“Egan-Jones”) in recommending that Americold shareholders vote AGAINST the reelection of long-tenured Chairman Mark Patterson at the Company’s upcoming 2026 Annual Meeting...
-
The Winn-Dixie Company wins 18 national awards for private label innovation and customer experience
JACKSONVILLE, Fla.--(BUSINESS WIRE)--The Winn-Dixie Company wins 18 national awards for private label innovation and customer experience...